Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro
- 1 January 2008
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 16 (1) , 293-302
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- A Mechanistic View of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-like PeptidaseJournal of Molecular Biology, 2007
- Anti-SARS drug screening by molecular dockingAmino Acids, 2006
- From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virusBioorganic & Medicinal Chemistry Letters, 2006
- Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitorBioorganic & Medicinal Chemistry Letters, 2005
- pH-dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure AnalysesJournal of Molecular Biology, 2005
- Crystal Structures of the Main Peptidase from the SARS Coronavirus Inhibited by a Substrate-like Aza-peptide EpoxideJournal of Molecular Biology, 2005
- Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main ProteasesPLOS Biology, 2005
- “Teaching old drugs to kill new bugs”: structure-based discovery of anti-SARS drugsBiochemical and Biophysical Research Communications, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- The Protein Data BankNucleic Acids Research, 2000